Grant J, North S
Rutland House Referrals, 4 Abbotsfield Road, St Helens, Merseyside, WA94HU, UK.
VRCC Veterinary Referrals, Laindon, Essex, UK.
Aust Vet J. 2016 Jun;94(6):197-202. doi: 10.1111/avj.12444.
To identify any prognostic factors that may be associated with the long-term survival of dogs diagnosed with tonsillar squamous cell carcinoma (TSCC).
The medical records of 15 dogs treated for TSCC were reviewed retrospectively. The signalment, presenting signs, clinical stage, treatments and outcome were documented.
The overall median survival time (MST) of the dogs in the study was 243 days. There was a 1-and 2-year survival of 40% and 20%, respectively. The results of initial staging had a significant effect on survival, as dogs with only one tonsil affected and no evidence of metastatic disease had a longer MST (637.5 days) than the dogs with local (MST: 134 days) or distant (MST: 75 days) metastatic disease or bilateral tonsillar involvement at the time of initial presentation. Prolonged survival times were reported for dogs undergoing surgery and adjunctive chemotherapy (MST: 464.5 days) for treatment of their TSCC.
This is the first veterinary study demonstrating an association between prognosis of patients with TSCC and stage at the time of presentation, with long survival times demonstrated for dogs with early-stage disease following an initial treatment protocol that included surgery and chemotherapy. There was no clear association between long survival and additional surgeries for progressive disease; however; further investigation is warranted.
确定与诊断为扁桃体鳞状细胞癌（TSCC）的犬长期存活可能相关的任何预后因素。
回顾性分析15只接受TSCC治疗的犬的病历。记录品种、临床表现、临床分期、治疗方法及预后情况。
研究中犬的总体中位生存时间（MST）为243天。1年和2年生存率分别为40%和20%。初始分期结果对生存有显著影响，因为仅一侧扁桃体受累且无转移疾病证据的犬的MST（637.5天）比初次就诊时出现局部转移（MST：134天）或远处转移（MST：75天）或双侧扁桃体受累的犬更长。接受手术及辅助化疗治疗TSCC的犬报告有较长的生存时间（MST：464.5天）。
这是第一项兽医研究，证明TSCC患者的预后与就诊时的分期之间存在关联，对于遵循包括手术和化疗的初始治疗方案的早期疾病犬显示出较长的生存时间。长期生存与针对进展性疾病的额外手术之间没有明确关联；然而，有必要进行进一步调查。
